Please assess the completion status of the following clinical trial:

Trial Title: Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of DSM-IV ADHD by K-SADS-PL and confirmed by clinical interview~* Clinical Global Impression-Severity score of at least 4 for ADHD~* Resided with primary caretaker for at least 6 months prior to study entry~Exclusion Criteria:~* History of autism, pervasive developmental disorder, chronic tic disorder, psychosis, or bipolar disorder~* Current major depression or panic disorder~* Systolic or diastolic blood pressure at screening greater than the 95th percentile or less than the 5th percentile for age and body mass index (BMI)~* Any medical condition that might make stimulant or alpha agonist therapy medically inadvisable~* Need for chronic use of other medications with central nervous system effects~* Pregnant, breastfeeding, or beyond menarche and has a positive urine pregnancy test~* History of structural heart defects, syncope, or fainting while exercising~* Clinically significant cardiac abnormality as determined by echocardiogram (ECG) at study entry~* Mental retardation as determined by clinical functional assessment and an IQ estimate of less than 70 based on Wechsler Adult Intelligence Scale (WAIS) subtests

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: Guan-Guan+Placebo (Type: ACTIVE_COMPARATOR): weeks 1-4: Guanfacine weeks 5-8: Guanfacine + Placebo
- Group 2: Placebo-Placebo+DMPH (Type: ACTIVE_COMPARATOR): weeks 1-4: Placebo weeks 5-8: Placebo+DMPH
- Group 3: Guan-Guan+DMPH (Comb) (Type: EXPERIMENTAL): weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH

Based on this trial design, predict the completion outcome and termination type (if applicable).